Frio Pharmaceuticals


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Frio Pharmaceuticals Inc. is dedicated to oral-systemic health. Frio Pharmaceuticals Inc was spun out of Biomedical Development Corporation (BDC), its research affiliate, in 1999 to manufacture and sell a dental waterline cleaner. This platform technology has evolved into a pipeline of pharmaceuticals to treat oral diseases and interrupt the disease process. BDC (parent company) will assign the technology to Frio Pharmaceuticals (recipient). The goal of this project is to commercialize a broad-s...Show all

Frio Pharmaceuticals Inc. is dedicated to oral-systemic health. Frio Pharmaceuticals Inc was spun out of Biomedical Development Corporation (BDC), its research affiliate, in 1999 to manufacture and sell a dental waterline cleaner. This platform techn...Show all

Company (Alive / Active)

Phone:

Fax:

San Antonio, 78201
Texas, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Frio Pharmaceuticals $0M Nov 30, 2018
See all 19 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Frio Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Supernus Pharmaceuticals

Rockville, Maryland, United States
IPO / Went publicSupernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The company is developing several product candidates in neurology and psychiatry to address market opportunities in epilepsy and attention deficit hyperactivity disorder, or ADHD, including ADHD patients with impulsiveaggression. Supernus intends to market product candidates in the United States through our a focused sale...Show allLogin to see details

Somaxon Pharmaceuticals

San Diego, California, United States
AcquiredSomaxon Pharmaceuticals is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Our lead product candidate is Silenor (doxepin) for the treatment of insomnia. Silenor is a sleep-specific, low-dose (3mg and 6mg), oral tablet formulation of doxepin that is patent-protected for use in insomnia. In contrast...Show allLogin to see details
See all 19 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)